Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death

A case-control study nested in the Japan Collaborative Cohort (JACC) study

Kenji Wakai, Yoshinori Ito, Koji Suzuki, Akiko Tamakoshi, Nao Seki, Masahiko Ando, Kotaro Ozasa, Yoshiyuki Watanabe, Takaaki Kondo, Yoshikazu Nishino, Yoshiyuki Ohno, M. Mori, Y. Motohashi, I. Tsuji, Y. Nakamura, H. Iso, H. Mikami, S. Hashimoto, Y. Inaba, Y. Hoshiyama & 30 others H. Suzuki, H. Shimizu, H. Toyoshima, S. Tokudome, S. Kikuchi, A. Koizumi, T. Kawamura, T. Miki, C. Dale, K. Sakata, T. Nose, N. Hayakawa, T. Yoshimura, K. Fukuda, N. Okamoto, H. Shio, T. Kitagawa, T. Kuroki, K. Tajima, T. Shimamoto, H. Tanaka, S. Hisamichi, M. Nakao, T. Suzuki, T. Hashimoto, T. Ishibashi, Kunio Aoki, Haruo Sugano, Kei Nakachi, Shuji Hashimoto

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

To elucidate the roles of insulin-like growth factors (IGFs) in the development of lung cancer, we conducted a case-control study nested within the Japan Collaborative Cohort Study. Serum samples were collected at baseline from 39 140 men and women between 1988 and 1990. We measured serum IGF-I, IGF-II, and IGF-binding protein-3 (IGFBP-3) in 194 case subjects who subsequently died from lung cancer during an 8-year follow-up and in 9351 controls. The odds ratios (ORs), adjusted for smoking and other covariates, were smaller with higher levels of IGF-II and IGFBP-3. The ORs across quartiles were 0.41 (95% confidence interval [CI], 0.27-0.63), 0.47 (0.31-0.71), and 0.67 (0.46-0.98) for IGF-II (trend P=0.018), and 0.55 (95% CI, 0.37-0.81), 0.54 (0.36-0.82), and 0.67 (0.45-1.01) for IGFBP-3 (trend P=0.037). These peptides were not independently related to lung cancer risk when mutually adjusted. The risk was increased in the highest vs. the lowest quartile of IGF-I only after controlling for IGFBP-3 (OR, 1.74; 95% CI, 1.08-2.81). Limiting subjects to those followed for ≥3 years strengthened the negative associations of IGF-II and IGFBP-3, whereas the ORs for IGF-I generally decreased. A higher level of circulating IGFBP-3 and/or IGF-II may decrease lung cancer risk. Elevated serum IGF-I may increase the risk, but this could partly be attributable to latent tumors.

Original languageEnglish
Pages (from-to)1279-1286
Number of pages8
JournalJapanese Journal of Cancer Research
Volume93
Issue number12
DOIs
Publication statusPublished - 01-12-2002

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Somatomedins
Insulin-Like Growth Factor II
Case-Control Studies
Lung Neoplasms
Japan
Cohort Studies
Insulin-Like Growth Factor I
Serum
Odds Ratio
Confidence Intervals
Smoking
Peptides
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Wakai, Kenji ; Ito, Yoshinori ; Suzuki, Koji ; Tamakoshi, Akiko ; Seki, Nao ; Ando, Masahiko ; Ozasa, Kotaro ; Watanabe, Yoshiyuki ; Kondo, Takaaki ; Nishino, Yoshikazu ; Ohno, Yoshiyuki ; Mori, M. ; Motohashi, Y. ; Tsuji, I. ; Nakamura, Y. ; Iso, H. ; Mikami, H. ; Hashimoto, S. ; Inaba, Y. ; Hoshiyama, Y. ; Suzuki, H. ; Shimizu, H. ; Toyoshima, H. ; Tokudome, S. ; Kikuchi, S. ; Koizumi, A. ; Kawamura, T. ; Miki, T. ; Dale, C. ; Sakata, K. ; Nose, T. ; Hayakawa, N. ; Yoshimura, T. ; Fukuda, K. ; Okamoto, N. ; Shio, H. ; Kitagawa, T. ; Kuroki, T. ; Tajima, K. ; Shimamoto, T. ; Tanaka, H. ; Hisamichi, S. ; Nakao, M. ; Suzuki, T. ; Hashimoto, T. ; Ishibashi, T. ; Aoki, Kunio ; Sugano, Haruo ; Nakachi, Kei ; Hashimoto, Shuji. / Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death : A case-control study nested in the Japan Collaborative Cohort (JACC) study. In: Japanese Journal of Cancer Research. 2002 ; Vol. 93, No. 12. pp. 1279-1286.
@article{7b1bfed4e6104f92ab0c2e24ff34281e,
title = "Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: A case-control study nested in the Japan Collaborative Cohort (JACC) study",
abstract = "To elucidate the roles of insulin-like growth factors (IGFs) in the development of lung cancer, we conducted a case-control study nested within the Japan Collaborative Cohort Study. Serum samples were collected at baseline from 39 140 men and women between 1988 and 1990. We measured serum IGF-I, IGF-II, and IGF-binding protein-3 (IGFBP-3) in 194 case subjects who subsequently died from lung cancer during an 8-year follow-up and in 9351 controls. The odds ratios (ORs), adjusted for smoking and other covariates, were smaller with higher levels of IGF-II and IGFBP-3. The ORs across quartiles were 0.41 (95{\%} confidence interval [CI], 0.27-0.63), 0.47 (0.31-0.71), and 0.67 (0.46-0.98) for IGF-II (trend P=0.018), and 0.55 (95{\%} CI, 0.37-0.81), 0.54 (0.36-0.82), and 0.67 (0.45-1.01) for IGFBP-3 (trend P=0.037). These peptides were not independently related to lung cancer risk when mutually adjusted. The risk was increased in the highest vs. the lowest quartile of IGF-I only after controlling for IGFBP-3 (OR, 1.74; 95{\%} CI, 1.08-2.81). Limiting subjects to those followed for ≥3 years strengthened the negative associations of IGF-II and IGFBP-3, whereas the ORs for IGF-I generally decreased. A higher level of circulating IGFBP-3 and/or IGF-II may decrease lung cancer risk. Elevated serum IGF-I may increase the risk, but this could partly be attributable to latent tumors.",
author = "Kenji Wakai and Yoshinori Ito and Koji Suzuki and Akiko Tamakoshi and Nao Seki and Masahiko Ando and Kotaro Ozasa and Yoshiyuki Watanabe and Takaaki Kondo and Yoshikazu Nishino and Yoshiyuki Ohno and M. Mori and Y. Motohashi and I. Tsuji and Y. Nakamura and H. Iso and H. Mikami and S. Hashimoto and Y. Inaba and Y. Hoshiyama and H. Suzuki and H. Shimizu and H. Toyoshima and S. Tokudome and S. Kikuchi and A. Koizumi and T. Kawamura and T. Miki and C. Dale and K. Sakata and T. Nose and N. Hayakawa and T. Yoshimura and K. Fukuda and N. Okamoto and H. Shio and T. Kitagawa and T. Kuroki and K. Tajima and T. Shimamoto and H. Tanaka and S. Hisamichi and M. Nakao and T. Suzuki and T. Hashimoto and T. Ishibashi and Kunio Aoki and Haruo Sugano and Kei Nakachi and Shuji Hashimoto",
year = "2002",
month = "12",
day = "1",
doi = "10.1111/j.1349-7006.2002.tb01235.x",
language = "English",
volume = "93",
pages = "1279--1286",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "12",

}

Wakai, K, Ito, Y, Suzuki, K, Tamakoshi, A, Seki, N, Ando, M, Ozasa, K, Watanabe, Y, Kondo, T, Nishino, Y, Ohno, Y, Mori, M, Motohashi, Y, Tsuji, I, Nakamura, Y, Iso, H, Mikami, H, Hashimoto, S, Inaba, Y, Hoshiyama, Y, Suzuki, H, Shimizu, H, Toyoshima, H, Tokudome, S, Kikuchi, S, Koizumi, A, Kawamura, T, Miki, T, Dale, C, Sakata, K, Nose, T, Hayakawa, N, Yoshimura, T, Fukuda, K, Okamoto, N, Shio, H, Kitagawa, T, Kuroki, T, Tajima, K, Shimamoto, T, Tanaka, H, Hisamichi, S, Nakao, M, Suzuki, T, Hashimoto, T, Ishibashi, T, Aoki, K, Sugano, H, Nakachi, K & Hashimoto, S 2002, 'Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: A case-control study nested in the Japan Collaborative Cohort (JACC) study', Japanese Journal of Cancer Research, vol. 93, no. 12, pp. 1279-1286. https://doi.org/10.1111/j.1349-7006.2002.tb01235.x

Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death : A case-control study nested in the Japan Collaborative Cohort (JACC) study. / Wakai, Kenji; Ito, Yoshinori; Suzuki, Koji; Tamakoshi, Akiko; Seki, Nao; Ando, Masahiko; Ozasa, Kotaro; Watanabe, Yoshiyuki; Kondo, Takaaki; Nishino, Yoshikazu; Ohno, Yoshiyuki; Mori, M.; Motohashi, Y.; Tsuji, I.; Nakamura, Y.; Iso, H.; Mikami, H.; Hashimoto, S.; Inaba, Y.; Hoshiyama, Y.; Suzuki, H.; Shimizu, H.; Toyoshima, H.; Tokudome, S.; Kikuchi, S.; Koizumi, A.; Kawamura, T.; Miki, T.; Dale, C.; Sakata, K.; Nose, T.; Hayakawa, N.; Yoshimura, T.; Fukuda, K.; Okamoto, N.; Shio, H.; Kitagawa, T.; Kuroki, T.; Tajima, K.; Shimamoto, T.; Tanaka, H.; Hisamichi, S.; Nakao, M.; Suzuki, T.; Hashimoto, T.; Ishibashi, T.; Aoki, Kunio; Sugano, Haruo; Nakachi, Kei; Hashimoto, Shuji.

In: Japanese Journal of Cancer Research, Vol. 93, No. 12, 01.12.2002, p. 1279-1286.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death

T2 - A case-control study nested in the Japan Collaborative Cohort (JACC) study

AU - Wakai, Kenji

AU - Ito, Yoshinori

AU - Suzuki, Koji

AU - Tamakoshi, Akiko

AU - Seki, Nao

AU - Ando, Masahiko

AU - Ozasa, Kotaro

AU - Watanabe, Yoshiyuki

AU - Kondo, Takaaki

AU - Nishino, Yoshikazu

AU - Ohno, Yoshiyuki

AU - Mori, M.

AU - Motohashi, Y.

AU - Tsuji, I.

AU - Nakamura, Y.

AU - Iso, H.

AU - Mikami, H.

AU - Hashimoto, S.

AU - Inaba, Y.

AU - Hoshiyama, Y.

AU - Suzuki, H.

AU - Shimizu, H.

AU - Toyoshima, H.

AU - Tokudome, S.

AU - Kikuchi, S.

AU - Koizumi, A.

AU - Kawamura, T.

AU - Miki, T.

AU - Dale, C.

AU - Sakata, K.

AU - Nose, T.

AU - Hayakawa, N.

AU - Yoshimura, T.

AU - Fukuda, K.

AU - Okamoto, N.

AU - Shio, H.

AU - Kitagawa, T.

AU - Kuroki, T.

AU - Tajima, K.

AU - Shimamoto, T.

AU - Tanaka, H.

AU - Hisamichi, S.

AU - Nakao, M.

AU - Suzuki, T.

AU - Hashimoto, T.

AU - Ishibashi, T.

AU - Aoki, Kunio

AU - Sugano, Haruo

AU - Nakachi, Kei

AU - Hashimoto, Shuji

PY - 2002/12/1

Y1 - 2002/12/1

N2 - To elucidate the roles of insulin-like growth factors (IGFs) in the development of lung cancer, we conducted a case-control study nested within the Japan Collaborative Cohort Study. Serum samples were collected at baseline from 39 140 men and women between 1988 and 1990. We measured serum IGF-I, IGF-II, and IGF-binding protein-3 (IGFBP-3) in 194 case subjects who subsequently died from lung cancer during an 8-year follow-up and in 9351 controls. The odds ratios (ORs), adjusted for smoking and other covariates, were smaller with higher levels of IGF-II and IGFBP-3. The ORs across quartiles were 0.41 (95% confidence interval [CI], 0.27-0.63), 0.47 (0.31-0.71), and 0.67 (0.46-0.98) for IGF-II (trend P=0.018), and 0.55 (95% CI, 0.37-0.81), 0.54 (0.36-0.82), and 0.67 (0.45-1.01) for IGFBP-3 (trend P=0.037). These peptides were not independently related to lung cancer risk when mutually adjusted. The risk was increased in the highest vs. the lowest quartile of IGF-I only after controlling for IGFBP-3 (OR, 1.74; 95% CI, 1.08-2.81). Limiting subjects to those followed for ≥3 years strengthened the negative associations of IGF-II and IGFBP-3, whereas the ORs for IGF-I generally decreased. A higher level of circulating IGFBP-3 and/or IGF-II may decrease lung cancer risk. Elevated serum IGF-I may increase the risk, but this could partly be attributable to latent tumors.

AB - To elucidate the roles of insulin-like growth factors (IGFs) in the development of lung cancer, we conducted a case-control study nested within the Japan Collaborative Cohort Study. Serum samples were collected at baseline from 39 140 men and women between 1988 and 1990. We measured serum IGF-I, IGF-II, and IGF-binding protein-3 (IGFBP-3) in 194 case subjects who subsequently died from lung cancer during an 8-year follow-up and in 9351 controls. The odds ratios (ORs), adjusted for smoking and other covariates, were smaller with higher levels of IGF-II and IGFBP-3. The ORs across quartiles were 0.41 (95% confidence interval [CI], 0.27-0.63), 0.47 (0.31-0.71), and 0.67 (0.46-0.98) for IGF-II (trend P=0.018), and 0.55 (95% CI, 0.37-0.81), 0.54 (0.36-0.82), and 0.67 (0.45-1.01) for IGFBP-3 (trend P=0.037). These peptides were not independently related to lung cancer risk when mutually adjusted. The risk was increased in the highest vs. the lowest quartile of IGF-I only after controlling for IGFBP-3 (OR, 1.74; 95% CI, 1.08-2.81). Limiting subjects to those followed for ≥3 years strengthened the negative associations of IGF-II and IGFBP-3, whereas the ORs for IGF-I generally decreased. A higher level of circulating IGFBP-3 and/or IGF-II may decrease lung cancer risk. Elevated serum IGF-I may increase the risk, but this could partly be attributable to latent tumors.

UR - http://www.scopus.com/inward/record.url?scp=0036958017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036958017&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2002.tb01235.x

DO - 10.1111/j.1349-7006.2002.tb01235.x

M3 - Review article

VL - 93

SP - 1279

EP - 1286

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 12

ER -